2016_Head & Neck COURSE BOOK

Anti-EGFR failed in second-line

Study

N Regimens

ORR Median PFS 3.9% 2.7% 7.6%

Median Survival NA 5.6 months 6 months 6.7 months

Stewart JCO 2009 161 158 167

Methotrexate versus Gefitinib 250 mg/day versus Gefitinib 500 mg/day

Argiris JCO 2009 136 134 Docetaxel + placebo versus Machiels Lancet Oncol 2011 95 191 BSC or methotrexate versus

Docetaxel + gefitinib 6.2% 12.5% NA 6 months 7.3 months Zalutumumab 1.1% 6.3% 8.4 weeks 9.9 weeks* 5.2 months 6.7 months * Statistically significa